{
    "nctId": "NCT01535040",
    "briefTitle": "Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking",
    "officialTitle": "Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "Retention",
    "eligibilityCriteria": "INCLUSION CRITERIA:\n\n* Survivors of non-metastatic breast, prostate, or colorectal cancer, or stage I/II non-small cell lung cancer\n* Age \u2265 18\n* Smoked 100 tobacco cigarettes over lifetime at time of first interview, have smoked 10 or more cigarettes per day on most days over the past month\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky \u2265 70%)\n* Ability to understand and the willingness to sign a written informed consent document\n* Agrees to adhere to the study protocol and attend the required clinic visits\n* Negative serum pregnancy test within 10 days prior to registration in women with child-bearing potential; women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation\n* Women who are currently breast-feeding are not eligible for this study\n\nExclusion Criteria:\n\n* Use of chewing tobacco, pipe tobacco, snuff, or any other non-cigarette tobacco product is not allowed\n* No patients with clinically significant uncontrolled medical conditions (e.g., unstable angina, myocardial infarction, transient ischemic attack \\[TIA\\], or cerebral vascular accident \\[CVA\\]) within past 3 months\n* Creatinine \u2265 2 times upper limit of normal (ULN) in last six months\n* Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvate transaminase (SGPT) \u2265 3 times ULN in last six months\n* Current uncontrolled hypertension \u2265 160/90 mm Hg\n* Excessive alcohol abuse defined as more than 5 drinks per day for men and 4 drinks per day for women\n* Major medical or psychiatric illness which, in the opinion of the investigator, would prevent completion of treatment or would interfere with follow-up\n* History of allergic reactions attributed to memantine\n\nPRIOR CONCURRENT THERAPY:\n\n* Six months post definitive treatment (except for ongoing hormonal or targeted therapies)\n* Patients currently must not be taking Nicotine Replacement Therapy (NRT) and agree to not start NRT for the duration of the study\n* Patients currently taking antidepressant or antianxiety medications must have been on a stable dose for 4 weeks prior to registration\n* Patients currently receiving the following medications are not eligible: anticonvulsant agents (e.g., phenytoin, carbamazepine, gabapentin, etc.); antiparkinsonian agents (e.g., Levo Dopa, ropinirole); neuroleptic agents (e.g., risperidone, quetiapine); carbonic anhydrase inhibitors (e.g., Diamox\u00ae and Sequels\u00ae)\n* Memantine should not be combined with other N-methyl d-aspartate (NMDA) antagonists (amantadine, ketamine, and dextromethorphan)\n* Participants may not be receiving any other investigational agents\n* No current use of illegal drugs or use of prescription medications for non-medical reasons",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}